{"id":59979,"date":"2026-03-20T11:54:44","date_gmt":"2026-03-20T03:54:44","guid":{"rendered":"https:\/\/flcube.com\/?p=59979"},"modified":"2026-03-20T11:54:46","modified_gmt":"2026-03-20T03:54:46","slug":"samsung-bioepis-expands-sandoz-partnership-global-deal-for-five-biosimilars-including-entyvio-copycat-sb36","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59979","title":{"rendered":"Samsung Bioepis Expands Sandoz Partnership \u2013 Global Deal for Five Biosimilars Including Entyvio Copycat SB36"},"content":{"rendered":"\n

Samsung Bioepis Co., Ltd.<\/strong> has expanded its strategic partnership<\/strong> with Sandoz AG<\/strong> (SWX: SDZ<\/a>), entering into a global licensing agreement<\/strong> to develop and commercialize up to five biosimilar candidates<\/strong> including SB36<\/strong>, a biosimilar referencing Takeda Pharmaceutical’s Entyvio (vedolizumab)<\/strong> \u2013 deepening the collaboration between the South Korean biologics manufacturer and the Swiss generic drug giant.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Deal Type<\/strong><\/td>Expanded global licensing partnership<\/td><\/tr>
Licensor<\/strong><\/td>Samsung Bioepis Co., Ltd. (Samsung Bio)<\/td><\/tr>
Licensee<\/strong><\/td>Sandoz AG (SWX: SDZ)<\/td><\/tr>
Scope<\/strong><\/td>Up to five biosimilar candidates<\/strong><\/td><\/tr>
Lead Asset<\/strong><\/td>SB36<\/strong> \u2013 biosimilar of vedolizumab (Entyvio)<\/td><\/tr>
Other Assets<\/strong><\/td>Four additional biosimilars (undisclosed)<\/td><\/tr>
Financial Terms<\/strong><\/td>Confidential<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

SB36 \u2013 Vedolizumab Biosimilar Profile<\/h2>\n\n\n\n
Attribute<\/th>Detail<\/th><\/tr><\/thead>
Reference Product<\/strong><\/td>Entyvio (vedolizumab) \u2013 Takeda Pharmaceutical Co., Ltd.<\/td><\/tr>
Development Stage<\/strong><\/td>Pre\u2011clinical<\/td><\/tr>
Mechanism<\/strong><\/td>Anti\u2011\u03b14\u03b27 integrin monoclonal antibody<\/td><\/tr>
Indications<\/strong><\/td>Adult patients with: Crohn’s disease<\/strong>, ulcerative colitis<\/strong>, pouchitis<\/strong><\/td><\/tr>
Reference Market<\/strong><\/td>Entyvio generated ~US$3.5 billion annually (Takeda’s flagship GI biologic)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Partnership Evolution \u2013 Samsung Bioepis + Sandoz Track Record<\/h2>\n\n\n\n
Date<\/th>Collaboration<\/th>Asset<\/th>Status<\/th><\/tr><\/thead>
September 2023<\/strong><\/td>Commercialization partnership<\/td>Pyzchiva<\/strong> (ustekinumab biosimilar \u2013 Stelara copycat)<\/td>EU launch:<\/strong> July 2024; US launch:<\/strong> February 2025<\/td><\/tr>
December 2025<\/strong><\/td>Regional commercialization<\/td>Epysqli<\/strong> (eculizumab biosimilar \u2013 Soliris knockoff)<\/td>MEA region<\/strong> (Middle East & Africa)<\/td><\/tr>
March 2026<\/strong><\/td>Expanded global deal<\/strong><\/td>SB36 + 4 additional biosimilars<\/strong><\/td>Development\/commercialization phase<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n